Pulse Explore Journal Club Debates Trending Researchers

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Home Explore Journal Club Trending

⌘+K

AVITHRAPID - Standard Operating Procedure - Cytotoxicity Cell Viability assay | Synapse

May 22, 2026Open Access

View Full Paper

AVITHRAPID - Standard Operating Procedure - Cytotoxicity Cell Viability assay

Key Points

The aim is to outline a procedure to evaluate the cytotoxic effects of various test compounds.
Describes a luminescence-based assay for measuring cell viability.
Applicable within the AVITHRAPID project for screening test compounds.
Demonstrates the effectiveness of the luminescence assay for detecting cytotoxicity of test compounds.

Abstract

This Standard Operating Procedure (SOP) defines the method for evaluating the cytotoxicity of test compounds within the AVITHRAPID project using a luminescence-based cell viability assay.

Ask AI

Helpful

Bookmark

Share

View Full Paper

Cite This Study

Ilenia Varasi (Wed,) studied this question.

synapsesocial.com/papers/6a0ff412d674f7c03778d137 https://doi.org/https://doi.org/10.5281/zenodo.20306268

Ask AI

Helpful

Bookmark

Share

View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1AVITHRAPID - Standard Operating Procedure - Cytotoxicity evaluation – virucidal compounds2026
2AVITHRAPID - Standard Operating Procedure - Antiviral activity evaluation by qPCR – Virucidal compounds2026
3AVITHRAPID - Standard Operating Procedure - Antiviral activity evaluation by CPE – Virucidal compounds2026
4AVITHRAPID - Standard Operating Procedure - Antiviral activity evaluation on HEV by qPCR – Virucidal compounds2026
5AVITHRAPID - Standard Operating Procedure - PLC3 cells differentiation before HEV infection2026